A meta-analysis of 85 randomized clinical trials involving 70,543 participants found that sodium-glucose cotransporter 2 (SGLT2) inhibitors were associated with small but statistically significant increases in hemoglobin and hematocrit levels compared with control treatments, although the clinical significance of these changes remains unclear. The trials had a median follow-up of […]
Early initiation of sodium-glucose cotransporter-2 (SGLT2) inhibitors after Takotsubo syndrome was associated with significantly lower all-cause mortality in a large real-world U.S. study, although reductions in cardiovascular complications were not observed. Using the TriNetX U.S. Collaborative Network, researchers identified adults diagnosed with Takotsubo syndrome between 2015 and 2025 and compared […]
A rigorous cohort study utilizing Taiwan’s National Health Insurance Database provides robust evidence that SGLT2 inhibitors offer superior multi-organ protection for the complex population of patients with both type 2 diabetes and liver cirrhosis. Among 24,259 adults (average age 64.7 years; 33.9% female) followed for a median of 2.3 years, […]